These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Efficacy of prophylactic irradiation to the contralateral testis for patients with advanced-stage primary testicular lymphoma: an analysis of outcomes at a single institution. Tokiya R; Yoden E; Konishi K; Kamitani N; Hiratsuka J; Koresawa R; Hirose T; Sano F; Tokunaga H; Kondo T; Wada H; Sugihara T Int J Hematol; 2017 Oct; 106(4):533-540. PubMed ID: 28612278 [TBL] [Abstract][Full Text] [Related]
26. MACOP-B +/- radiation therapy for diffuse large cell lymphoma. Analysis of the Stanford results according to prognostic indices. Bartlett NL; Kwak LW; Horning SJ Cancer; 1993 Jun; 71(12):4034-42. PubMed ID: 7685238 [TBL] [Abstract][Full Text] [Related]
27. Outcome and patterns of failure in testicular lymphoma: a multicenter Rare Cancer Network study. Zouhair A; Weber D; Belkacémi Y; Ketterer N; Dietrich PY; Villà S; Scandolaro L; Bieri S; Studer G; Delacretaz F; Girardet C; Mirimanoff RO; Ozsahin M; Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):652-6. PubMed ID: 11849786 [TBL] [Abstract][Full Text] [Related]
28. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol]. Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405 [TBL] [Abstract][Full Text] [Related]
29. The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen. Shipp MA; Yeap BY; Harrington DP; Klatt MM; Pinkus GS; Jochelson MS; Rosenthal DS; Skarin AT; Canellos GP J Clin Oncol; 1990 Jan; 8(1):84-93. PubMed ID: 1688615 [TBL] [Abstract][Full Text] [Related]
30. Predictors of local recurrence after rituximab-based chemotherapy alone in stage III and IV diffuse large B-cell lymphoma: guiding decisions for consolidative radiation. Jegadeesh N; Rajpara R; Esiashvili N; Shi Z; Liu Y; Okwan-Duodu D; Flowers CR; Khan MK Int J Radiat Oncol Biol Phys; 2015 May; 92(1):107-12. PubMed ID: 25863758 [TBL] [Abstract][Full Text] [Related]
31. Randomized study comparing doxorubicin, cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (ACOMLA) with cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin (CHOP-B) in the treatment of diffuse histiocytic lymphoma. Newcomer LN; Cadman EC; Nerenberg MI; Chen M; Bertino JR; Farber LR; Prosnitz LR Cancer Treat Rep; 1982 Jun; 66(6):1279-84. PubMed ID: 6177407 [TBL] [Abstract][Full Text] [Related]
32. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Todeschini G; Secchi S; Morra E; Vitolo U; Orlandi E; Pasini F; Gallo E; Ambrosetti A; Tecchio C; Tarella C; Gabbas A; Gallamini A; Gargantini L; Pizzuti M; Fioritoni G; Gottin L; Rossi G; Lazzarino M; Menestrina F; Paulli M; Palestro M; Cabras MG; Di Vito F; Pizzolo G Br J Cancer; 2004 Jan; 90(2):372-6. PubMed ID: 14735179 [TBL] [Abstract][Full Text] [Related]
33. Intensive weekly combination chemotherapy for patients with intermediate-grade and high-grade non-Hodgkin's lymphoma. Sweetenham JW; Mead GM; Whitehouse JM J Clin Oncol; 1991 Dec; 9(12):2202-9. PubMed ID: 1720454 [TBL] [Abstract][Full Text] [Related]
35. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. Longo DL; DeVita VT; Duffey PL; Wesley MN; Ihde DC; Hubbard SM; Gilliom M; Jaffe ES; Cossman J; Fisher RI J Clin Oncol; 1991 Jan; 9(1):25-38. PubMed ID: 1702144 [TBL] [Abstract][Full Text] [Related]
36. Primary mediastinal large B-cell lymphoma: the need for prospective controlled clinical trials. Bieri S; Roggero E; Zucca E; Bertoni F; Pianca S; Sanna P; Pedrinis E; Bernier J; Cavalli F Leuk Lymphoma; 1999 Nov; 35(5-6):537-44. PubMed ID: 10609791 [TBL] [Abstract][Full Text] [Related]
37. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era. Ferreri AJ; Bruno-Ventre M; Donadoni G; Ponzoni M; Citterio G; Foppoli M; Vignati A; Scarfò L; Sassone M; Govi S; Caligaris-Cappio F Br J Haematol; 2015 Mar; 168(5):654-62. PubMed ID: 25312994 [TBL] [Abstract][Full Text] [Related]
38. [Treatment of primary mediastinal large B-cell lymphomas]. Schneider T; Tóth E; Molnár Z; Várady E; Deák B; Horváth A; Horváth GI; Eid H; Schneider K; Lovey J; Keresztes S; Esik O; Lengyel Z; Rosta A Orv Hetil; 2004 Dec; 145(50):2531-7. PubMed ID: 15662753 [TBL] [Abstract][Full Text] [Related]
39. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442 [TBL] [Abstract][Full Text] [Related]
40. Non-Hodgkin's lymphoma of the paranasal sinuses: clinical and pathological features, and response to combined-modality therapy. Hausdorff J; Davis E; Long G; Hoppe R; van der Pas M; Lassman C; Kamel O; Jacobs C Cancer J Sci Am; 1997; 3(5):303-11. PubMed ID: 9327155 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]